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Abnormal vascular smooth muscle (VSM) growth is central in the pathophysiology
of vascular disease yet fully effective therapies to curb this growth are lacking.
Recent findings from our lab and others support growth control of VSM by adenosine
monophosphate (AMP)-based approaches including the metabolic sensor AMP-activated
protein kinase (AMPK) and cAMP-dependent protein kinase (PKA). Molecular crosstalk
between AMPK and PKA has been previously suggested, yet the extent to which this
occurs and its biological significance in VSM remain unclear. Considering their common
AMP backbone and similar signaling characteristics, we hypothesized that crosstalk exists
between AMPK and PKA in the regulation of VSM growth. Using rat primary VSM cells
(VSMC), the AMPK agonist AICAR increased AMPK activity and phosphorylation of the
catalytic Thr172 site on AMPK. Interestingly, AICAR also phosphorylated a suspected
PKA-inhibitory Ser485 site on AMPK, and these cumulative events were reversed by
the PKA inhibitor PKI suggesting possible PKA-mediated regulation of AMPK. AICAR
also increased PKA activity in a reversible fashion. The cAMP stimulator forskolin
increased PKA activity and completely ameliorated Ser/Thr protein phosphatase-2C
activity, suggesting a potential mechanism of AMPK modulation by PKA since inhibition
of PKA by PKI reduced AMPK activity. Functionally, AMPK inhibited serum-stimulated cell
cycle progression and cellular proliferation; however, PKA failed to do so. Moreover, AMPK
and PKA reduced PDGF-β-stimulated VSMC migration. Collectively, these results show
that AMPK is capable of reducing VSM growth in both anti-proliferative and anti-migratory
fashion. Furthermore, these data suggest that AMPK may be modulated by PKA and that
positive feedback may exist between these two systems. These findings reveal a discrete
nexus between AMPK and PKA in VSM and provide basis for metabolically-directed
targets in reducing pathologic VSM growth.
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INTRODUCTION
Aberrant vascular smooth muscle (VSM) growth is a pivotal
mechanism underlying numerous pathologies including the evo-
lution of atherosclerotic plaque, pressure- and/or flow-mediated
hypertrophy, stent-induced hyperplasia, and iatrogenic restenosis
after intervention (Majesky, 1994; Insull, 2009; Wang et al., 2010).
The “de-differentiation” of VSM cells (VSMCs) from a normally
cytostatic, contractile phenotype to a synthetic phenotype with
enhanced proliferation, migration, and secretion of extracellular
matrix is a major player in the establishment and progression of
these disorders. In spite of many studies aimed at reducing the
individual components that make up this activated phenotype,
abnormal VSMC growth remains a critical contributor to vas-
cular pathology and comprehensive, clinically feasible therapies
have yet to be identified.
Adenosine monophosphate-activated protein kinase (AMPK)
is a key metabolic sensor that responds to cellular energy deple-
tion and stress by inhibiting many ATP-reducing processes,
thereby promoting ATP synthetic processes within the cell
(Rubin et al., 2005; Sanders et al., 2007). AMPK is a
ubiquitously-expressed heterotrimeric enzyme that responds to
a rise in the AMP:ATP ratio via activation by upstream kinases
such as anti-tumorigenic LKB1 and transforming growth factor
β (TGFβ)-activated kinase 1 (TAK1). AMPK can also respond in
AMP-independent manner via Ca+2/calmodulin-dependent pro-
tein kinase (Rubin et al., 2005; Momcilovic et al., 2006; Hardie,
2007; Sanders et al., 2007). Mechanistically, phosphorylation of
the catalytic alpha domain at Thr 172 has been reported to be
essential for full kinase activity (Woods et al., 2003; Hardie, 2007,
2011). Alternate alpha moieties, such as Ser 173 (Djouder et al.,
2010) or 485 (Hurley et al., 2006), have been suggested to serve
inhibitory functions on AMPK activity. Functionally, AMPK has
been reported to enhance vascular relaxation (Rossoni et al.,
2011) and inhibit vessel growth (Nagata et al., 2004). AMPK
has also been implicated in G0/G1 cytostasis in commercial
VSMCs (Igata et al., 2005). These intriguing reports suggesting
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growth-reducing capacities of AMPK justify further investigation
into AMPK as a potential therapeutic target against VSM growth
disorders.
Cyclic adenosine monophosphate (cAMP) and its canonical
downstream kinase PKA are critical signaling factors that exert
a variety of functional effects in cardiac and vascular tissues. It
is reported that Thr 197 of the catalytic subunit of PKA is phos-
phorylated in proportion to PKA activity (Steinberg et al., 1993;
Shen et al., 2004) and is a better indicator of activity than the
previously reported Ser 338 moiety (Shoji et al., 1983); however,
the exact phospho-specific mechanisms of activation of PKA and
their impact on kinase efficacy in VSM remain unclear.
It has been previously suggested that a biochemical relation-
ship may exist between AMPK and PKA (Hurley et al., 2006;
Djouder et al., 2010; Kim et al., 2010), although the exact nature
of this relationship and the extent to which they relate in VSM is
uncertain. The cyclic AMP/PKA system, like AMPK, has ability to
enhance vasodilation (Zhang et al., 2010; Valero et al., 2011) and
inhibit vessel growth (D’Souza et al., 2003; Hewer et al., 2011).
Additionally, PKA and AMPK exhibit capacity either discretely
or collectively to regulate cellular metabolism, and coordination
between their pathways has been reported to exist either syner-
gistically (Cohen and Hardie, 1991; Dyck et al., 1999; Richter
et al., 2003) or antagonistically (Watt et al., 2006; Djouder et al.,
2010), depending the metabolic demands and the tissue type.
Cellular proliferation is normally under tight metabolic con-
trol, and although little work has been done to elucidate the
relationship between these two signaling systems in the control
of cellular growth, crosstalk has been implicated in the inhibi-
tion of cancer cell hyperplasia (Han et al., 2009; Lucchi et al.,
2011). Therefore, it is intriguing to speculate that crosstalk may
exist between PKA and AMPK and that this crosstalk may be of
biological significance in its ability to modulate VSM growth.
The purpose of this study was to further characterize the
AMPK and PKA signaling pathways and to determine what
role(s) they play in the collaborative inhibition of VSM growth.
Our hypothesis was that AMPK and PKA possess biochemical
crosstalk and, in turn,may act cooperatively to inhibit VSMCpro-
liferation and migration. Novel results show that AMPK controls
VSMC proliferation and migration and that these events are reg-
ulated at least in part by PKA. These findings offer insight into
a potential metabolic signaling network that may provide new
therapeutic targets for the reduction of vascular growth disorders.
MATERIALS AND METHODS
MATERIALS
AICAR was purchased from Toronto Research Company (North
York, ON) and Invitrogen (Carlsbad, CA), Compound C was
purchased from Invitrogen, forskolin, and PKI were purchased
from Enzo Life Sciences (Farmingdale, NY), and IBMX was
purchased from Calbiochem (Darmstadt, Germany). All pri-
mary antibodies were purchased from Abcam (Cambridge, MA)
or Cell Signaling (Danvers, MA) and were targeted against
the following: total AMPK (1:1000), pAMPKThr172 (1:1000),
pAMPKSer485 (1:5000), total ACC (1:1000), pACCSer80 (1:1000),
total PKA (1:1000), pPKAThr197 (1:1000), total VASP (1:1000),
or pVASPSer157 (1:1000), and α-tubulin (1:1000) or beta-actin
(1:1000). Antibodies were diluted in IRDye blocking buffer
(Rockland; Gilbertsville, PA). For In-Cell Western analysis IRDye
anti-rabbit secondary antibodies (1:1000; Rockland) were used
for protein detection while Draq 5 (1:10000; Cell Signaling) and
Sapphire 7 (1:1000; Li-Cor; Lincoln, NE) were used for DNA
staining and protein normalization. Propidium iodide (PI) and
RNAse for cell cycle analysis were purchased from Invitrogen.
CELL CULTURE
This investigation was approved by the Institutional Animal
Care and Use Committee and conformed to the Guide for the
Care and Use of Laboratory Animals (US National Institutes of
Health, Publication No. 85-23, revised 1996). Primary VSMCs
were isolated from thoracic aortae of male Sprague-Dawley rats
(∼125 g; Charles River Labs) by collagenase and elastase diges-
tion and characterized morphologically as previously described
(Durante et al., 1993; Joshi et al., 2011). VSMCs were cultured
in Dulbecco’s Modified Eagles Medium (DMEM) supplemented
with Fetal Bovine Serum (FBS, 0.5–10%), 2mM L-glutamine,
and 1:500 dilution of 50 ug/mL Primocin at 37◦C in 95% air/5%
CO2. Cells were serially split and used only through passage 6 to
avoid onset of phenotypic switching (Browner et al., 2004). For all
assays, n is calculated as at least three separate trials each with at
least three wells (or reads) per assay from serially split clonal cells.
ASSESSMENT OF AMPK AND PKA ACTIVITY
VSMCs were seeded in 96-well plates and, once confluent, were
treated with specified pharmacologic agents. After treatment,
cells were formalin-fixed, and protein phosphorylation was deter-
mined by In-Cell Western analysis as recently described (Joshi
et al., 2011; Adderley et al., 2012). Briefly, fixed cells were perme-
abilized with 0.1% Triton-X, blocked with IRDye blocking buffer
and treated with rabbit anti-rat primary antibodies for 1 h at RT.
Target proteins were IR-labeled and DNA was stained for protein
normalization. Fluorescence was detected and analyzed using Li-
Cor Odyssey Infrared Imaging System and software. Additionally,
traditional Western blots were performed on primary cell lysates
as previously described (Tulis et al., 2000; Mendelev et al., 2009)
to verify In-Cell Western data for select experiments. For spe-
cific activity, treated cells were lysed in buffer [50mM Tris, pH
6.8; 1% SDS; 0.1% Triton; protease inhibitor cocktail (Thermo);
phosphate inhibitor cocktail (Thermo)], and added to wells of
a 96-well microtiter plate. ELISA-based activity assays were per-
formed per manufacturer’s instructions. Briefly, for AMPK (MBL
International, Woburn, MA), activity was assessed using a mouse
insulin receptor substrate phospho-serine 789 reporter with HRP
chemiluminescence at 450 nm (Tang et al., 2011; Lin et al., 2012).
For PKA (Enzo Life Sciences), activity was measured by tetra-
methylbenzidine substrate color development proportional to
PKA phosphotransferase activity and measured at 450 nm as
described (Cai et al., 2010).
PHOSPHATASEACTIVITY
Cells were harvested in phosphatase inhibitor-free buffer, pre-
pared according to manufacturer’s suggestion (Invitrogen), and
added to wells of microtiter plates containing 6,8-difluoro-
4methyl-umbelliferyl phosphate substrate. When activated by
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phosphatases, DiFMU was generated in proportion to phos-
phatase activity, which was read at 450 nm. For specific (PP-2A
and PP-2C) phosphatase activities, additional components were
added to the buffer per manufacturer’s directions that allowed
for activity analyses of specific phosphatases within the lysate
(Kawaguchi et al., 2001; Pastula et al., 2003).
CELL CYCLE ANALYSIS
Cells were plated in 12-well plates at 80,000 cells/well in com-
plete media until 50% confluent. Cells were quiesced in 0.5%
FBS for 24 h followed by treatment in complete growth media
(DMEM, 10% FBS, Primocin) containing select pharmacologic
agents for 24 h. As previously stated (Joshi et al., 2012) cells
were trypsinized and stained with PI (Invitrogen) per man-
ufacturer’s recommendations. The fraction of cells present in
each phase of the cell cycle was assessed by flow cytome-
try (Accuri C6 Flow Cytometer) using CFlow Plus software
(Accuri).
CELL PROLIFERATION ANALYSIS
VSMCs were plated in 6-well plates at 180,000 cells/well in com-
plete media until 50% confluent. Cells were quiesced in 0.5%
FBS for 24 h followed by treatment in complete growth media for
48 h as described above. Cells were trypsinized and proliferation
and viability were assessed through automated cell counting with
trypan blue exclusion staining (ViCell, Beckman) (Tulis, 2008).
CELL MIGRATION ANALYSIS
Following protocols previously described with minor modifica-
tions (Liu et al., 2008; Joshi et al., 2011), VSMCs were seeded
at 180,000 cells/ml in the upper chamber of a Fluorblok tran-
swell system (BD) in complete media and allowed to adhere. Cells
were then treated for 1 h following staining with Cell Tracker
Green (10 uM; Invitrogen). Serum-free media was applied to the
upper chamber containing the same original treatment and 10 ng
PDGF-β was applied to the bottom chamber as a chemoattrac-
tant (Yang et al., 2006). Cell migration was assessed from time
0 through 18 h by bottom-read fluorescence at 525 nm (Tecan
Infinite M200) with each time point relative fluorescence units
(RFU) normalized to time = 0 RFU for each respective condition.
Net migration was calculated as a fold change of the total migra-
tion for each condition over total control (vehicle) migration at
18 h.
STATISTICAL ANALYSES
Data were analyzed using Excel 2011 (Microsoft) and Sigma Plot
11.2 (SPSS, Inc.). One-Way analysis of variance (ANOVA) and
Tukey’s post-hoc multiple comparison tests were used to detect
changes between individual groups. Two-Way ANOVA with mul-
tiple comparisons and Tukey’s post-hoc tests were used for protein
phosphatase (PP) analysis, migration, and cell cycle analysis to
detect significance among groups. For each assay, “n” is calculated
from a minimum of 3 experiments, each consisting of 3 individ-
ual wells (and thus, reads) from serially-split, clonal parent cell
generations. Data are expressed as mean ± standard error of the
mean (SEM), with a p < 0.05 considered statistically significant.
RESULTS
AMPK ENHANCES PKA ACTIVITY
Initial experiments focused on activation of AMPK in pri-
mary VSMCs. Treatment of cells with 1mM of the AMPK
FIGURE 1 | AICAR increases AMPK signaling in rat primary VSMCs.
Cells were treated with AICAR (1mM), Compound C (CC; 10 uM) or their
combination for 60min and AMPK Thr172 phosphorylation (A), ACC Ser80
phosphorylation (B), and AMPK activity (C) were measured. AICAR
significantly increased phosphorylation of both AMPK Thr172 (A) and ACC
Ser80 (B) as well as AMPK activity (C), all in CC-reversible fashion. CC also
significantly reduced basal levels of phosphorylated AMPK Thr172, ACC
Ser80, and AMPK activity. In all cases addition of the PKA-inhibitor PKI also
significantly decreased AMPK signaling and activity. Expression data were
normalized to DNA content (Draq 5/Sapphire 700) and presented as
phosphorylated AMPK/total AMPK (A) or phosphorylated ACC/total ACC
(B). Activity was measured via absorbance at 450nm. P -values less than
0.05 were considered statistically significant for n = 5–7 per group.
∗p < 0.05 compared to control; ∗∗∗p < 0.001 compared to control;
#p < 0.05 compared to respective activator treatment.
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agonist AICAR (60min), a concentration previously docu-
mented to effectively induce AMPK activity in vascular cells
without observable side-effects (Goirand et al., 2007; Chang
et al., 2010), significantly enhanced catalytic phosphorylation
(Woods et al., 2003) of AMPK Thr172 (Figure 1A) as well as
acetyl Co-A carboxylase (ACC) at Ser80 (Figure 1B), a tradi-
tional marker of AMPK activity (Witters et al., 1991). Both
basal and AICAR-stimulated pAMPK Thr172 and pACC Ser80
were inhibited by 30min pre-treatment with Compound C
(CC; 10 uM), a selective AMPK inhibitor verified for use in
VSM (Chang et al., 2010; Song et al., 2011; Sung and Choi,
2011). Intriguingly, inhibition of PKA with PKI (10 uM) also
reversed the AICAR-induced increase in both AMPK Thr172
and ACC Ser80 phosphorylation (Figures 1A,B). In agreement,
using an AMPK-specific activity assay AICAR induced a signifi-
cant increase in AMPK activity that was reversed by CC and PKI
under stimulated conditions and by CC under basal conditions
(Figure 1C).
Considering relative novelty of the In-Cell Western approach,
traditional Western blotting was used in primary cell lysates to
support In-Cell Western results for these initial experiments.
VSMC lysates were probed for pAMPK Thr172 and pACC
Ser80 as indicators of AMPK activity. As shown in Figure 2,
AICAR (1mM, 60min) increased AMPK catalytic phosphory-
lation and downstream ACC signaling (Figures 2A,B). AICAR-
mediated increases in pAMPK and pACC were then reduced
to control levels in the presence of CC (data not shown).
These findings agree with our In-Cell Western results and
confirm utility of the In-Cell Western approach in primary VSM
preparations.
Studies were then performed to evaluate the influence of
AMPK on PKA signaling. AICAR induced a significant increase
in vasodilator-stimulated phosphoprotein (VASP) Ser157 phos-
phorylation, a reported marker of active PKA (Eckert and
Jones, 2007; Joshi et al., 2011), and this was completely
reversed by CC (Figure 3A). Additionally, co-treatment of
AICAR with a PKA inhibitor, PKI (10 uM; 60min), also
reversed the AICAR-induced phosphorylation of VASP Ser157
(Figure 3A). Furthermore, using an activity assay AICAR
induced a significant increase in PKA activity, which was
also fully reversed by CC and PKI (Figure 3B). Neither basal
levels of pVASP Ser157 nor PKA activity were affected by
CC.
PKA PRESERVES AMPK ACTIVITY
While phosphorylation of PKA at Thr197 is suggested to be
indicative of catalytic activity (Steinberg et al., 1993), neither
the adenylyl cyclase agonist Forskolin (FSK, 10 uM; 60min) nor
AICAR induced changes in phosphorylation of this site (data not
shown). However, treatment of VSMCs with FSK with or with-
out the broad phosphodiesterase (PDE) inhibitor IBMX (10 uM;
60min) induced a significant increase in pVASP Ser157, and this
was reversed by 10 uM of the PKA inhibitor PKI (Figure 4A). In
addition, using an activity assay, while FSK alone induced a non-
significant increase in PKA activity, addition of IBMX induced
a significant increase in PKA activity that was reversed by PKI
FIGURE 2 | AICAR increases AMPK signaling in rat primary VSMC
lysates. Cells were treated with AICAR (1mM) for 60min and AMPK Thr172
phosphorylation (A) and ACC Ser80 phosphorylation (B) were measured by
traditional Western blotting using IR-linked antibodies. AICAR significantly
increased phosphorylation of both AMPK Thr172 (A) and ACC Ser80 (B).
Phosphorylated protein levels were normalized to α-Tubulin and data presented
as fold change over control values. P -values less than 0.05 were considered
statistically significant for n = 3 per group. ∗∗p < 0.01 compared to control.
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FIGURE 3 | AMPK enhances PKA activity. Cells were treated with AICAR
(1mM), Compound C (CC; 10 uM) or a combination of both, and/or PKI
(10uM) for 60min, and phosphorylation of VASP Ser157 (A) and PKA
activity (B) were measured. In-Cell Western analysis revealed that AICAR
significantly increased VASP Ser157 phosphorylation (A). A PKA activity
assay revealed that AICAR increased PKA activity (B). Both analyses
revealed full reversal with concomitant CC and/or PKI. Data are presented
as phosphorylated VASP/total VASP and normalized to DNA content (Draq
5/Sapphire 700) or absorbance at 450nm for activity. P -values less than
0.05 were considered statistically significant for n = 5–7 per group.
∗∗∗p < 0.001 compared to control; #p < 0.05 compared to respective
activator treatment.
(Figure 4B). Additionally, concomitant treatments of FSK and
AICAR significantly increased PKA activity (Figure 4B).
Next, studies were performed to evaluate if PKA mediates
changes in AMPK signaling. FSK alone failed to alter pAMPK
Thr172; however, when PDE activity was inhibited by IBMX, a
significant increase in pAMPK Thr172 was observed (Figure 5A).
Intriguingly, synergistic responses in pAMPK Thr172, pACC
Ser80, and specific AMPK activity were observed with co-
treatments of FSK and AICAR (Figure 5). Also of note, PKI
alone induced a significant inhibitory effect on basal AMPK
activity, which returned to control levels with FSK co-treatment
(Figures 5A,C).
FIGURE 4 | FSK increases PKA signaling in rat primary VSMCs. Cells
were treated with FSK (10 uM), PKI (10 uM), or FSK and PKI or IBMX
(10uM) or AIC (1mM) for 60min, and pVASP Ser157 phosphorylation and
PKA activity were determined. In-Cell Westerns revealed that FSK
significantly increased pVASP Ser157 alone or in the presence of IBMX
and/or AICAR, and these were largely reversed with the PKA inhibitor PKI
(A). A PKA activity assay revealed that FSK with IBMX or AIC synergistically
increased PKA activity (B). Data are presented as phosphorylated
VASP/total VASP and normalized to DNA content (Draq 5/Sapphire 700) or
absorbance at 450nm for activity. P -values less than 0.05 were considered
statistically significant for n = 3–5 per group. ∗∗∗p < 0.001 compared to
control; #p < 0.05 compared to respective activator treatment.
Considering that phosphorylation at Ser485 has been associ-
ated with an inhibition of AMPK activity (Stricker et al., 2010;
Ning et al., 2011), we investigated pAMPK Ser485 expression
under both AMPK- and PKA-stimulated and -inhibited condi-
tions. In primary VSMCs, AICAR induced a significant increase
in pAMPK Ser485, which was fully reversed by CC (Figure 6A).
CC alone failed to significantly alter basal pAMPK Ser485 lev-
els. While FSK with or without IBMX failed to significantly alter
Ser485 phosphorylation, treatment with PKI alone significantly
reduced basal pAMPK Ser485, which returned to control levels
with concomitant FSK treatment (Figure 6B).
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FIGURE 5 | PKA increases AMPK activity in VSMCs. Cells were treated
with FSK (10uM), PKI (10 uM), or a combination of FSK and PKI or IBMX
(10uM) or AIC (1mM) for 60min. Phosphorylation of AMPK Thr172 and
ACC Ser80 were measured by In-Cell Western (A) and (B) and AMPK
activity was measured by pAMPK-specific activity assay (C). FSK alone
failed to significantly increase AMPK Thr172 or ACC Ser80 phosphorylation
or AMPK activity; however, in the presence of IBMX or AICAR all were
significantly elevated. PKI alone significantly reduced both pAMPK Thr172
and activity. Data are presented as phosphorylated AMPK/total AMPK and
normalized to DNA content (Draq 5/Sapphire 700) or absorbance at 540nm
for activity. P -values less than 0.05 were considered statistically significant
for n = 5–7 per group. ∗p < 0.05 compared to control; ∗∗∗p < 0.001
compared to control.
PKA INHIBITS PROTEIN PHOSPHATASES
Serine/Threonine PPs, in particular PP-2A and PP-2C (Kemp
et al., 2003), have been reported to modulate AMPK activity
via kinase dephosphorylation. Therefore, we assessed the ability
of PKA to inhibit Ser/Thr PP activity as a possible mechanism
of PKA-mediated modulation of AMPK activity. Surprisingly,
treatment of VSMCs with AICAR steadily increased global PP
activity in significant fashion compared to vehicle-treated con-
trol lysates (Figure 7A). Intriguingly, FSK treatment completely
inhibited global PP activity in VSMC lysates compared to con-
trols (Figure 7A). With addition of NiCl2 (1mM) to the reaction
buffer to specifically monitor PP-2A activity (Pastula et al., 2003),
we found that AMPK specifically activated PP-2A in AICAR-
treated lysates compared to controls while no difference was
detected in FSK-treated cells (Figure 7B). Likewise, when MgCl2
(20mM) was added to the reaction buffer to selectively moni-
tor PP-2C (Pastula et al., 2003), we found that FSK specifically
and completely inhibited PP-2C levels compared to controls with
no differences detected in AICAR-treated lysates (Figure 7C).
Importantly, cumulative reductions in PP activity observed in
these experiments (global, PP-2A, PP-2C) were reversible with
simultaneous CC- or PKI-inhibition of AMPK or PKA, respec-
tively (data not shown for clarity).
COOPERATIVE SIGNALING INHIBITS VSMC PROLIFERATION AND
MIGRATION
The functional impact of these signaling events was assessed
in VSMCs by examination of chemotactic cell migration and
cellular proliferation. The influence of AMPK signaling on
PDGF-β-stimulated cell migration was assessed using a modified
Boyden transwell chemotactic assay over 18 h. AICAR (1mM)
significantly reduced the number of migratory cells which was
fully reversed with CC (Figure 8). Interestingly, while only a
trend (p = 0.102) toward anti-migration was observed with FSK
(10 uM) across the entire 18 h experiment, Two-Way ANOVA
revealed that the net migration at 18 h was statistically signifi-
cant compared to controls and was reversed with PKI (Figure 8).
Of note, both CC and PKI alone showed no significance across
time or at 18 h compared to vehicle controls (data not shown for
clarity).
Cell cycle progression and cell proliferation and viability were
examined, respectively, by flow cytometry and automated cell
counting with trypan blue exclusion staining. Cell cycle analy-
sis following 24 h serum stimulation revealed AICAR significantly
inhibited progression of cells from the S- to G2/M-phase, mani-
fested as reduced cell numbers in G2/M and elevated cell num-
bers in S (Figures 9A,B), and these were fully reversed by CC
(Figure 9A). FSK did not significantly reduce G2/M cell popu-
lations or increase G0/G1-phase cells (Figures 9A,B). Automated
cell counts after 48 h serum stimulation revealed that AICAR sig-
nificantly reduced cell numbers (Figure 9C); however, CC failed
to reverse this effect (data not shown). As with the cell cycle data,
while a trend was observed FSK alone did not significantly alter
cell numbers compared to vehicle controls (Figure 9C).
DISCUSSION
Findings in this study support our hypothesis that AMPK, in
conjunction with PKA, has capacity to inhibit growth of VSM.
We show that AMPK inhibits proliferation and migration of rat
primary VSMCs, and mechanistic data suggest that these growth-
mitigating effects of AMPK are at least partly regulated by PKA.
Novel findings also reveal that AMPK can reciprocally modulate
PKA activity, suggesting that crosstalk exists between these two
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FIGURE 6 | AICAR increases phosphorylation of AMPK at Ser485 in
PKA-independent fashion. (A) Cells were treated with AICAR (1mM),
Compound C (CC; 10uM) or a combination of both for 60min, or (B) with
FSK (10uM), PKI (10uM) or a combination of both, or IBMX (10 uM), or
AICAR (1mM) for 60min. In-Cell Western analyses revealed that
(A) pAMPK Ser485 was elevated with AICAR in a CC-reversible fashion.
While FSK with/without IBMX had no effect on pAMPK Ser485, FSK +
AICAR did significantly increase pAMPK Ser485. Intriguingly, PKI alone
significantly decreased Ser485 phosphorylation. Data are presented as
phosphorylated AMPK/total AMPK and normalized to DNA content (Draq
5/Sapphire 700). P -values less than 0.05 were considered statistically
significant for n = 5–7 per group. ∗p < 0.05 compared to control;
∗∗∗p < 0.001 compared to control; #p < 0.05 compared to respective
activator treatment.
pivotal signaling factors. It has been reported in adipocytes and
endothelial cells that a biochemical relationship exists between
AMPK and PKA (Hurley et al., 2006; Djouder et al., 2010; Kim
et al., 2010); however, this relationship has not been established
in VSM. Since both cAMP/PKA and AMPK act to regulate cel-
lular metabolism in response to intra- and extra-cellular signals
(Cohen and Hardie, 1991; Dyck et al., 1999; Richter et al., 2003;
Watt et al., 2006; Djouder et al., 2010), it is reasonable to specu-
late that a signaling relationship exists between the two signaling
cascades in response to energy-consuming cellular processes as
proliferation and migration. A synergistic relationship between
AMPK and PKA has been suggested in the regulation of cancer
growth (Han et al., 2009; Lucchi et al., 2011), and each factor has
been implicated individually in VSM growth inhibition (Nagata
et al., 2004; Igata et al., 2005; Joshi et al., 2011); therefore, based
on the current study we propose a cooperative relationship exists
between AMPK and PKA in the control of VSM growth. Data pre-
sented here support our theory that AMPK acts to inhibit VSM
growth and that PKA acts as an adjuvant to maintain and/or
possibly enhance this capacity.
Using rat primary VSMCs, AMPK expression and activity were
successfully and specifically induced with AICAR, and this posi-
tively influenced the PKA pathway (Figures 1–3). Conversely, the
PKA system was successfully induced using FSK, and this led to
increased AMPK activity. Following establishment of treatments
to specifically modulate AMPK and PKA activity (Figures 1,
4) crosstalk between the two systems was investigated. AICAR
increased PKA activity in AMPK-specific fashion (Figure 3),
suggesting that AMPK has the ability to increase PKA activity
in VSMCs. Paradoxically, as shown in Figure 5 PKA also has the
ability to modulate AMPK activity. Although we were unable
to detect increases in AMPK Thr172 phosphorylation or AMPK
activity from FSK alone, as has been reported in other tissues
(Hurley et al., 2006; Mendelev et al., 2009; Djouder et al., 2010;
Stricker et al., 2010), under conditions of PDE blockade with
IBMX FSK did increase both AMPKThr172 phosphorylation and
activity. This may reflect robust basal PDE activity under cell
culture conditions as described recently (Adderley et al., 2012).
Additionally, a synergistic effect was observed with concomitant
AICAR and FSK treatments, suggesting these two may indeed
act cooperatively as biochemical signaling molecules. Moreover,
inhibition of PKA by PKI showed a significant reduction in both
AMPK phosphorylation and activity, and these were partially
restored with concomitant FSK treatment. These findings suggest
that PKA may not directly modulate AMPK activity by phospho-
rylation, but may do so indirectly in a non-Ser172-dependent
mechanism, and thusmaymaintain a basal level of AMPK activity
under stimulated conditions.
A suggested mechanism by which PKA may modulate AMPK
activity in vitro is by inhibitory phosphorylation of AMPK
at Ser485 (Hurley et al., 2006; Ning et al., 2011). We tested
AMPK Ser485 phosphorylation under stimulatory (10% FBS)
and growth-arrested (0.5% FBS) conditions with or without
AMPK or PKA stimulation. Our findings reveal that AICAR not
only increased catalytic T172 phosphorylation of AMPK but also
significantly increased Ser485 phosphorylation, which was com-
pletely reversed by CC (Figure 6). Furthermore, PKA inhibition
significantly reduced Ser485 phosphorylation, further suggesting
a possible regulatory role of PKA on AMPK. Serum-starved cells
showed a similar but much lower Ser485 phospho-reduction in
response to PKI, but failed to exhibit altered phosphorylation in
response to AICAR, CC, and/or FSK treatments (data not shown).
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FIGURE 7 | PKA inhibits global and isoform-specific Ser/Thr
phosphatase activity. Cell lysates were prepared from cells treated with
AICAR (1mM), or a combination of both AICAR and Compound C (CC;
10 uM) for 60min, or with FSK (10uM), or a combination of FSK and PKI
(10uM) for 60min. Phosphatase activity of diluted (1:10) lysate samples
was measured by DiFMUP fluorescence at 452nm after 10min of
incubation in the dark. Activity analysis revealed that AICAR induced while
FSK inhibited global Ser/Thr phosphatase activity compared to control
values (A). With addition of NiCl2 (1mM) to the reaction buffer,
PP-2A-specific activity was tested and revealed that AICAR significantly
elevated PP-2A activity (B). Similarly, with addition of MgCl2 (20mM), DTT
(2mM), and EGTA (1mM) to the assay buffer, PP-2C-specific activity was
assessed and revealed that FSK significantly inhibited its activity (C).
Two-Way ANOVA with Tukey’s post-hoc testing was used for multiple
comparisons across time points as well as within each treatment group.
P -values less than 0.05 across time within each group were considered
statistically significant for n = 3 per group. ∗∗p < 0.01 compared to control.
Our data suggest that AMPK Ser485 phosphorylation may act to
modulate AMPK activity and that PKA may play an important
role in regulating this site. In agreement, Hurley et al. showed
significant auto-phosphorylation of Ser485 in a cell-free system
after just 10min of incubation with ATP (Hurley et al., 2006).
FIGURE 8 | AMPK inhibits VSMC migration. Cells were labeled with
CellTracker Green and treated throughout the assay with AICAR (1mM),
Compound C (CC; 10uM) or a combination of both for 60min, or with FSK
(10 uM), PKI (10uM), or a combination of both for 60min, and cell migration
was determined using a modified Boyden chamber apparatus and
bottom-read fluorescence at 525nm through 18h. AICAR significantly
reduced cell migration across the entirety of the experiment and was
reversed by CC. When looking across all time points, FSK had no significant
effect on cell migration (p = 0.102); however, net migration at time = 18h
was significantly reduced with FSK. The mean score of the best curve fit at
18h is portrayed by histogram. Significance was determined by Two-Way
ANOVA (with Tukey’s post-hoc testing for multiple comparisons) across the
entirety of the 18h timeframe and at 18h with all time points compared to
vehicle. P -values less than 0.05 across time within each group were
considered statistically significant for n = 5–8 per group. ∗∗p < 0.01
compared to control; ∗∗∗p < 0.001 compared to control; #p < 0.05
compared to respective activator treatment.
Therefore, expanding on these data we suggest that Ser485 may
be a site for auto-phosphorylation and “self-inhibition” of AMPK
to fine-tune the dynamic metabolic conditions of stimulated cells
on a minute-by-minute basis.
For every kinase, the balance between “on” and “off” is
highly regulated and is largely mediated by dephosphorylation
by specific PPs. Phosphatase activity, in particularly PP-2A and
PP-2C (Kemp et al., 2003), are major contributors to the reduc-
tion of AMPK activity. In this light, we examined the ability
of PKA to inhibit global and isoform-specific Ser/Thr phos-
phatase activity. Here we show that PKA stimulation completely
inhibits global PP activity and more specifically PP-2C activ-
ity in primary VSMC lysates (Figure 7). Taken together with
our earlier data showing the PKA inhibition by PKI significantly
reduced pAMPK Thr172 and Ser485, a non-kinase mechanism
of PKA-mediated regulation of AMPK is likely. Therefore, we
suggest that in VSMCs PKA may indirectly mediate AMPK
activity via reduced PP-2C activity on AMPK thus inhibiting
kinase de-phosphorylation and de-activation. Conversely, spe-
cific PP-2A activity was significantly increased in AICAR-treated
cells (Figure 7B). While seemingly counterintuitive, we and oth-
ers (Janssens and Goris, 2001) suggest that PP-2A may play
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an inhibitory role on cell cycle progression via inactivation of
cyclin/CDK complexes providing a possible mechanism by which
AMPK acts to inhibit cell cycle progression as our data show
(Figure 9). Taken together, these biochemical findings suggest for
the first time in primary VSMCs that AMPK and PKA exhibit the
capacity for synergistic crosstalk, a finding that may play signif-
icant roles in the proposed AMPK-mediated inhibition of VSM
growth.
Complementing these biochemical data, functional roles for
the cooperative signaling between AMPK and PKA were exam-
ined. VSM proliferation and migration are functional mecha-
nisms underlying aberrant vessel growth. Data using a transwell
chemotactic assay (Figure 8) clearly show that AICAR signifi-
cantly inhibits PDGF-β-stimulated VSMC migration. This is the
first report demonstrating ability of AMPK to inhibitmigration of
VSMCs. Additionally, data show that AICAR increases the down-
regulatory phosphorylation of VASP at Thr157 (Figure 3A) a
protein responsible for actin polymerization, which provides an
intriguing hypothetical mechanism for how AMPK disrupts actin
dynamics required for migration to occur. Interestingly, after
Two-Way ANOVA evaluating time-dependent migration over
18 h FSK had no significant effect on VSMC migration com-
pared to controls; however, overall migration after 18 h showed
a significant FSK-mediated anti-migratory effect. Importantly,
the degree to which FSK-induced these anti-migratory effects
remained significantly higher (29.8 ± 3.6) than the AICAR-
mediated effects (8.9 ± 1.5) on VSMC migration. These func-
tional data well-support our biochemical data and together
give further credence to our hypothesis that PKA may act to
enhance AMPK activity in an indirect manner. In light of these
new findings, it is reasonable to postulate that the hereto-
fore PKA-mediated actions within VSMCs that act to modulate
proliferation and migration (Joshi et al., 2011) may indeed be
AMPK-mediated.
Upon activation, normally contractile VSMCs undergo a
phenotypic change and become synthetic and proliferative. Cell
FIGURE 9 | AMPK induces cell cycle arrest and inhibits VSMC
proliferation. Cells were treated with AICAR (1mM), with/without
Compound C (CC; 10uM), or with FSK (10 uM) with/without PKI (10 uM)
following overnight quiescence. Cell cycle progression was analyzed by
flow cytometry using the DNA stain propidium iodide after 24h (A) and
cell numbers were quantified after 48h by automated cell counting and
trypan blue exclusion (B). Representative peaks from flow cytometry and
histograms of these data illustrate that AICAR significantly inhibits cell
cycle progression from S to the G2/M phase, revealed by increased
numbers in S and reduced numbers in G2/M (A) and (B), and these
were fully reversed by CC (A). Cell cycle analysis revealed that FSK
had no effect on cell cycle progression in primary VSMCs (A) and (B).
Cell count analysis also revealed that AICAR significantly reduced cell
numbers after 48h, and while a trend was observed, Two-Way ANOVA
reveals that FSK had no significant effect on cell numbers after 48h (C).
P -values less than 0.05 were considered statistically significant after
multiple comparisons and Two-Way ANOVA for n = 3–5 per group.
∗∗p < 0.01 compared to control; ∗∗∗p < 0.001 compared to control
(control comparison was made within each stage of the cell cycle for
cell cycle analysis).
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cycle analysis after 24 h and automated cell counting after
48 h revealed that AICAR significantly decreased cell cycle pro-
gression resulting in a significant reduction in cell numbers
(Figure 9). Of note, while AICAR-induced cell cycle inhibition
was reversed with CC after 24 h, cell proliferation after 48 h
was not affected. A recent study by collaborating investigators
revealed that CC alone has capacity to inhibit VSMC prolifer-
ation (Mendelev et al., 2009; Peyton et al., 2011), perhaps due
to the irreversible inhibitory actions of CC on AMPK (Handa
et al., 2011), and in the current study we observed powerful
cytostatic effects of CC and AICAR that kept cell numbers at
reduced levels. Moreover, in our study while FSK failed to sig-
nificantly alter cell cycle progression and cell proliferation, a
trend toward cytostasis in PKI-reversible fashion was observed
(Figure 9). AMPK has been suggested to promote cell senes-
cence; however, these intriguing findings together with our bio-
chemical data suggest that while PKA stimulation alone may
not promote cytostasis, PKA may act to enhance AMPK activ-
ity thus supporting and/or promoting AMPK-mediated cytosta-
sis. These data provide further evidence for the importance of
AMPK in the inhibition of serum-stimulated VSMC growth
and shed new light on a signaling network that may pro-
vide robust growth reduction in a more specific and targetable
manner.
In conclusion, novel data presented here provide ample evi-
dence that AMPK and PKA communicate biochemically and
act in concert as a signaling network capable of controlling
growth of VSMCs. This signaling crosstalk may be impor-
tant in the control of cellular metabolism as has been pro-
posed by others (Cohen and Hardie, 1991; Dyck et al., 1999;
Richter et al., 2003; Watt et al., 2006; Djouder et al., 2010),
and our data highlight its potential importance in the con-
trol of VSM growth. The schematic in Figure 10 highlights the
proposed cooperative relationship by which AMPK and PKA
are believed to inhibit VSMC proliferation and migration. We
suggest that AMPK increases PKA activity and that PKA may
independently or in turn inhibit Ser/Thr PP-2C activity, thus
indirectly modulating AMPK activity. Additionally, these data
suggest that PKA may modulate AMPK activity by regulating
phosphorylation of a proposed inhibitory AMPK Ser485 site.
These findings suggest a reciprocal and feed-forward mechanism
by which PKA modulates AMPK activity in serum-stimulated
VSMCs to further potentiate the anti-growth properties associ-
ated with AMPK. In addition to its static effects on proliferation,
we show for the first time that AMPK has capacity to inhibit
VSMC migration, providing a functional mechanism for the pre-
vention of VSMC-mediated vessel remodeling following disease
or injury. Intriguingly, our data show an increase in proposed
PKA-specific VASP Ser157 phosphorylation, suggesting AMPK
may act directly or indirectly through increased PKA activa-
tion to inhibit VASP-directed actin polymerization necessary
for cell movement. Additionally, novel findings from this study
suggest that AMPK increases PP-2A activity in VSMCs, providing
a possible mechanism for AMPK-mediated cell cycle inhibi-
tion, a reported function of PP-2A. Altogether, these data eluci-
date a signaling network that has potential clinical importance
FIGURE 10 | Schematic depicting the proposed cooperative
relationship between AMPK and PKA in the control of VSM growth. In
this diagram blunt lines represent proposed inhibitory while arrows
represent proposed stimulatory mechanisms. Those pathways that were
not directly tested and remain part of the overall hypothesis of this report
are presented as dashed lines. Biochemical data described herein reveal
that AMPK increases PKA activity and reciprocally, that PKA may modulate
AMPK activity by regulation of proposed AMPK-inhibitory Ser485
phosphorylation. Furthermore, data show that PKA abrogates Ser/Thr
phosphatase-2C activity, which may play a crucial role in regulating AMPK
activity. Functional data confirm that AMPK reduces VSMC growth by
inhibiting cell proliferation and migration. Intriguingly, these data show an
increase in reported PKA-specific VASP Ser157 phosphorylation,
suggesting AMPK may act directly or indirectly through increased PKA
activation to inhibit VASP-directed actin polymerization necessary for cell
movement. Additionally, novel findings from this study suggest that AMPK
increases PP-2A activity in VSMCs, which provides a possible mechanism
for AMPK-mediated cell cycle inhibition, a reported function of PP-2A.
Altogether these findings illustrate important cooperative signaling
between AMPK and PKA in serum-stimulated VSMCs that may further
potentiate the anti-growth properties associated with AMPK.
as a foundation for current therapeutics targeting VSM growth
disorders.
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